Protocol Ledger

NCT04398134 · Phase II · TERMINATED

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

Interventional Phase II clinical trial protocol NCT04398134 sponsored by Assembly Biosciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-28 Enrollment: 88 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04398134
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)88 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04398134
Protocol FieldVerified Registry Value
NCT IdentifierNCT04398134
Consolidated Lead SponsorAssembly Biosciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment88 participants (ACTUAL)
Registered Start Date2020-08-28
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI